← All trials
NCT04673799
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2021
- Primary completion
- Oct 18, 2021
- Completion date
- Oct 18, 2021
- First posted
- Dec 17, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 144
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kunming Pharmaceuticals, Inc.Lead sponsor
- Shaanxi University of Chinese MedicineOverall official - principal investigator
- The Third Hospital of ChangshaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.